After a 2023 study linked GLP-1s to an increased risk for pancreatitis, gastroparesis, and bowel obstruction, other researchers did a retrospective study to reexamine the association.
WASHINGTON, DC — In contrast with a previous study that found glucagon-like peptide 1 receptor agonists associated with an increased risk for acute pancreatitis and bowel obstruction , a new retrospective study found no significant link to these complications. The new data did, however, reinforce an association between GLP-1s and gastroparesis and biliary disease , specifically gallstones.
Instead, Lui said, he and colleague Gengqing Song, MD,"just made it simple" and excluded anyone with diabetes or an A1c ≥ 6.5. They were identified in the database between 2011 and 2023. Researchers noted their first-ever occurrence of acute pancreatitis, bowel obstruction, gastroparesis, or biliary disease during the study period.. In addition to BMI, propensity score matching included demographics, alcohol use, smoking, hyperlipidemia, and abdominal surgery. A second analysis specifically did not match participants for BMI.
However,"I interpret the results with intestinal obstruction and pancreatitis as more inconclusive than no risk," he added.
Obese Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Biliary Disease Gallbladder Disease Abdominal Infection Pancreatitis Body Mass Index BMI Gastroparesis Weight Loss Weight Management Bariatric Surgery Obesity Surgery Weight Loss Surgery Bowel Obstruction Acute Pancreatitis Gallstone Cholelithiasis Clinical Research Clinical Trials
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Hims & Hers Health adds compounded GLP-1 injections to weight loss programThe GLP-1 market has faced supply constraints in recent months as the drugs like Ozempic and Wegovy skyrocket in popularity.
Read more »
Hims & Hers Health adds compounded GLP-1 injections to weight loss programThe GLP-1 market has faced supply constraints in recent months as the drugs like Ozempic and Wegovy skyrocket in popularity.
Read more »
Hims & Hers to offer compounded GLP-1 weight-loss injectionsHims & Hers Health is introducing access to compounded GLP-1 weight loss injections as Ozempic and Wegovy soar in popularity.
Read more »
Family Pressure To Lose Weight In Adolescence Linked to Internalized Weight StigmaAnuradha Varanasi is a freelance science writer. She writes on the intersection of health/medicine, racial disparities, and climate change. She earned an MA in Science Journalism from Columbia University in New York City.
Read more »
'Turbocharged' New Weight-Loss Drug Has Patients Losing 24% of Body WeightDigital destination for sophisticated men & women. Live your best life with expert tips and news on health, food, sex, relationships, fashion and lifestyle.
Read more »
No, GLP-1 Supplements *Are Not* the Same as Prescription Drugs Like OzempicLearn how GLP-1 weight loss medications like Wegovy work in the body and whether over-the-counter GLP-1 supplements are as effective.
Read more »